Key Takeaways Two peer-reviewed publications reported clinical data from the phase 3 INSIGHT program evaluating MYL-1701P in diabetic macular edema. In a 20-week extension study, patients who continued MYL-1701P and those who switched from reference aflibercept had comparable safety, efficacy, and immunogenicity outcomes. Exploratory subgroup analyses showed clinically comparable visual acuity and retinal thickness outcomes between MYL-1701P and reference aflibercept across most evaluated subgroups.
Filter by:
Eyewire News
Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD
Eyetube
Maria Berrocal, MD and Audina Berrocal, MD
This trimmed haptic solution without glued scleral fixation may be beneficial for patients with bilateral aphakia, microcornea, nystagmus, and vitreous opacity.
Supanji Supanji, MD, MSc, PhD; Dewi Fathin Romdhoniyyah, MD, PhD; Aurelia Priscilla Regita Putri, MD; Hifdza Faza Felisha, MD; Vera Nurohmah Indrawati, S.Si; Ummi Noor Hasanah, S.Kep., Ns; Handayani, S.Kep., Ns; Nurul Imawati, MD; Darmawan M. Sophian, MD; Imam Tiharyo, MD, MSc; Mohammad Nafis Sabirin Mara, MD; Firman Setya Wardhana, MD, MSc; and Muhammad Bayu Sasongko, MD, MEPID, PhD
Retina Today
Justin C. Muste, MD; David Fell, MD; Omesh P. Gupta, MD; and Shane Griffin, MD, MCR
Frédéric Aissani, MD
Kevin J. Corcoran, COE, CPC, CPMA, FNAO
View More
New Retina Radio is a place to hear stories about retina that are told nowhere else.
The RETINAWS panel led by Kourous Rezaei, MD, discuss techniques for vitreoretinal surgery and rare surgical cases.
Eyewire headlines are now available as a weekly podcast! Listen Now